Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours

Area of Science:

• Oncology
• Biochemistry
• Cancer Biology

Background:

• The lysyl oxidase (LOX) enzyme family is crucial for desmoplastic matrix formation in primary tumors and metastatic sites.
• Dysregulation of LOX enzymes contributes significantly to cancer progression and adverse patient outcomes.

Purpose of the Study:

• To review the role of LOX family dysregulation in solid cancers.
• To evaluate the preclinical therapeutic landscape targeting the LOX family.
• To discuss the potential of LOX enzymes as diagnostic and prognostic markers.

Main Methods:

• Literature review of studies on LOX enzymes in cancer.
• Analysis of preclinical data for LOX-targeting therapeutics.
• Evaluation of LOX family's role in tumor microenvironment and metastasis.

Main Results:

• LOX family enzymes are key drivers of desmoplastic matrix, promoting tumor growth and metastasis.
• Targeting LOX family enzymes is a developing strategy in anti-stromal cancer therapies.
• LOX family members show potential as biomarkers for cancer diagnosis and prognosis.

Conclusions:

• LOX family dysregulation is a critical factor in solid tumor progression and poor prognosis.
• Therapeutic targeting of LOX enzymes represents a promising avenue for improving cancer patient outcomes.
• The LOX family holds potential as valuable diagnostic and prognostic indicators in oncology.